



# Glucose Lowering Medications for Type 2 Diabetes

B.C. Provincial Academic Detailing Service

October 2015

## References (by section)

### Page 2: The evidence for glucose lowering medications in type 2 diabetes

1. Bennett W, Maruthur N, Singh Sonal, et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. *Ann Intern Med* 2011;154:602-613
2. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. *Ann Intern Med* 2007;147:386-99
3. Selvin E, Bolen S, Hsin-Chieh Y, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. *Arch Intern Med* 2008;168(19):2070-2080
4. Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2005, Issue 3. Art. No.:CD002966
5. Bousageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. *PLoS Med* 2014;9(4):e10001204
6. Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. *Diabetologia* 2012;55:2593-2603
7. Hemmingsen B, Schroll JB, Lund SS, et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2013, Issue 4. Art. No.:CD009008. WITHDRAWN: *Cochrane Database Syst Rev* 2015 Jul 29;7:CD009008
8. Hemmingsen B, Schroll JB, Wetterslev J, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trials sequential analysis. *CMAJ Open* 2014;2(3):E162-E175
9. Black C, Donnelly P, McIntyre L, et al. Meglitinide analogues for type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2007, Issue 2. Art. No.:CD004654
10. Van de Laar FA, Lucassen PLBJ, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2005, Issue 2. Art. No.:CD003639
11. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Pioglitazone for type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2006, Issue 4. Art. No.:CD006060
12. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Rosiglitazone for type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2007, Issue 3. Art. No.:CD006063
13. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2008, Issue 2. Art. No.:CD006739
14. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. *BMJ* 2012;344:e1369
15. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes. A systematic review and meta-analysis. *Ann Intern Med* 2013;159:262-274
16. Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2011, Issue 10. Art. No.:CD006423
17. Canadian Agency for Drugs and Technologies in Health. Second-line pharmacotherapy for type 2 diabetes-Update. Ottawa: The Agency; 2013 (CADTH optimal use report; vol.3, no.1a). [Internet]. [https://www.cadth.ca/sites/default/files/pdf/OP0512\\_DiabetesUpdate\\_Second-line\\_e.pdf](https://www.cadth.ca/sites/default/files/pdf/OP0512_DiabetesUpdate_Second-line_e.pdf) (accessed August 29, 2015)
18. Canadian Agency for Drugs and Technologies in Health. Third-line pharmacotherapy for type 2 diabetes-Update. Ottawa: The Agency; 2013 (CADTH optimal use report; vol.3, no.1b). [Internet]. [https://www.cadth.ca/sites/default/files/pdf/OP0512\\_Diabetes%20Update\\_Third-line\\_e.pdf](https://www.cadth.ca/sites/default/files/pdf/OP0512_Diabetes%20Update_Third-line_e.pdf) (accessed August 29, 2015)
19. Canadian Diabetes Associated Clinical Practice Guidelines Expert Committee. Targets for glycemic control. *Can J Diabetes* 2013;37:S31-S34
20. American Diabetes Association. Standards of Medical Care in Diabetes-2015. *Diabetes Care* 2015;38(1):S1-S94
21. U.S. Department of Veterans Affairs. VA/DoD Clinical Practice Guidelines. Management of Diabetes Mellitus in Primary Care (2010). [Internet]. <http://www.healthquality.va.gov/guidelines/cd/diabetes/> (accessed August 29, 2015)

*BC's Provincial Academic Detailing (PAD) Service is offered free of charge to health care professionals. The service is provided by health authorities and supported by the Ministry of Health. Relevant topics are identified in consultation with various groups. All written materials are externally reviewed by clinicians and experts in critical appraisal.*

22. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in Type 2 Diabetes. *N Engl J Med*; 2015;373:232-42
23. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with Type 2 Diabetes Mellitus. *N Engl J Med* 2013;369:1317-1326
24. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with Type 2 Diabetes. *N Engl J Med* 2013;369:1327-1335
25. Health Canada. Health Products and Food Branch. Guidance document: Standards for clinical trials in type 2 diabetes in Canada. 2007. [Internet]. [http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/clin/type2\\_diab-eng.php](http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/clin/type2_diab-eng.php) (accessed August 29, 2015)
26. U.S. Food and Drug Administration. Guidance for industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. 2008. [Internet]. <http://www.fda.gov/downloads/Drugs/Guidances/ucm071624.pdf> (accessed August 29, 2015)
27. U.S. Food and Drug Administration. Guidance for industry. Diabetes mellitus: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. [Internet]. <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf> (accessed August 29, 2015)
28. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus. 2010. [Internet]. [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2012/06/WC500129256.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf) (accessed August 29, 2015)
29. Gandhi G, Murad MH, Fukiyoshi A, et al. Patient-important outcomes in registered diabetes trials. *JAMA* 2008;299(21):2543-2549
30. U.S. Food and Drug Administration. Januvia Sitagliptin Phosphate Tablets. Approval Letter. NDA 21995. [Internet]. 2006. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2006/021995s000\\_APPROV.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_APPROV.pdf) (accessed August 29, 2015)
31. U.S. Food and Drug Administration. Onglyza Saxagliptin Tablets. Approval Letter. NDA 22350. [Internet]. 2009. [http://www.accessdata.fda.gov/drugsatfda\\_docs/applletter/2009/022350s000ltr.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/applletter/2009/022350s000ltr.pdf) (accessed August 29, 2015)
32. U.S. Food and Drug Administration. Tradjenta Linagliptin Tablets. Approval Letter. NDA 201280. [Internet]. 2011. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2011/201280Orig1s000Approv.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000Approv.pdf) (accessed August 29, 2015)
33. U.S. Food and Drug Administration. Nesina Alogliptin Tablets. Approval Letter. NDA 201280. [Internet]. 2013. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2013/022271Orig1s000Approv.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000Approv.pdf) (accessed August 29, 2015)
34. U.S. Food and Drug Administration. Invokana Canagliflozin Tablets. Approval Letter. NDA 204042. [Internet]. 2013. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2013/204042Orig1s000Approv.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000Approv.pdf) (accessed August 29, 2015)
35. U.S. Food and Drug Administration. Farxiga Dapagliflozin Tablets. Approval Letter. NDA 202293. [Internet]. 2014. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2014/202293Orig1s000Approv.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000Approv.pdf) (accessed August 29, 2015)
36. U.S. Food and Drug Administration. Jardiance Empagliflozin Tablets. Approval Letter. NDA 204629. [Internet]. 2014. [http://www.accessdata.fda.gov/drugsatfda\\_docs/applletter/2014/204629Orig1s000ltr.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/applletter/2014/204629Orig1s000ltr.pdf) (accessed September 15, 2015)
37. U.S. Food and Drug Administration. Victoza Liraglutide rDNA Injection. Approval Letter. NDA 22341. [Internet]. 2010. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2010/022341s000approv.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000approv.pdf) (accessed August 29, 2015)
38. U.S. Food and Drug Administration. Byetta Exenatide Injection. Approval Letter. NDA 21773. [Internet]. 2005. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2005/021773\\_Byetta\\_approv.PDF](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_approv.PDF) (accessed August 29, 2015)
39. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352:837-53
40. UK Prospective Diabetes Study (UKPDS) Group. VIII. Study design, progress and performance. *Diabetologia* 1991;34:877-890
41. Ewart RM. The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study. *BMJ* 2001;323:854-858
42. Nathan DM. Some answers, more controversy, from UKPDS. *Lancet* 1998;352:832-833

**Page 3: The evidence for glucose lowering strategies in type 2 diabetes**

1. Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycemic control versus targeting conventional glycemic control for type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2013, Issue 11. Art. No.:CD008143. WITHDRAWN: *Cochrane Database Syst Rev* 2015 Jul 29;7:CD008143
2. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. *BMJ* 2011;343:d4169
3. Coca SG, Ismail-Beigi F, Haq N, et al. Role of intensive glucose control in development of renal endpoints in type 2 diabetes: systematic review and meta-analysis. *Arch Intern Med* 2012;172(10):761-769
4. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008;358:2545-2559
5. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008;358:2560-2572
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352:837-53
7. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009;360:129-39

- Montori VM, Fernandez Balsells M. Glycemic control in type 2 diabetes: time for an evidence based about face? *Ann Intern Med* 2009;150:803-803

#### Page 4: Magnitude of Hemoglobin A1C Lowering and Dose Response

- Bennett W, Maruthur N, Singh Sonal, et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. *Ann Intern Med* 2011;154:602-613
- Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. *Ann Intern Med* 2007;147:386-99
- Canadian Agency for Drugs and Technologies in Health. Second-line pharmacotherapy for type 2 diabetes-Update. Ottawa: The Agency; 2013 (CADTH optimal use report; vol.3, no.1a). [Internet]. [https://www.cadth.ca/sites/default/files/pdf/OP0512\\_DiabetesUpdate\\_Second-line\\_e.pdf](https://www.cadth.ca/sites/default/files/pdf/OP0512_DiabetesUpdate_Second-line_e.pdf) (accessed August 29, 2015)
- Canadian Agency for Drugs and Technologies in Health. Second-line therapy for patients with diabetes inadequately controlled on metformin: a systematic review and cost-effectiveness analysis. Ottawa: The Agency;2010 (CADTH optimal therapy report; vol.4, issue 2). [Internet]. [https://www.cadth.ca/sites/default/files/pdf/C1110\\_SR\\_Report\\_final\\_e.pdf](https://www.cadth.ca/sites/default/files/pdf/C1110_SR_Report_final_e.pdf) (accessed August 29, 2015)
- Sherifali D, Nerenberg K, Pullenayegum E, et al. The effect of oral antidiabetic agents on A1c levels. *Diabetes Care* 2010;33:1859-1864
- Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes. A systematic review and meta-analysis. *Ann Intern Med* 2013;159:262-274
- Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. *BMJ* 2012;344:e1369
- Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2011, Issue 10. Art. No.:CD006423
- Park H, Park C, Kim Y, Rascati K. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta analysis. *Ann Pharmacother* 2012;46:1452-69
- Wu S, Sun F, Zhang Y, et al. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials. *J Clin Pharm Therap* 2014;39:7-13
- U.S. Food and Drug Administration. Onglyza (Saxagliptin) Tablets. Drug Approval Package. Medical Review. NDA 22350. [Internet]. 2009. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2009/022350s000\\_MedR\\_P1.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_MedR_P1.pdf); [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2009/022350s000\\_MedR\\_P2.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_MedR_P2.pdf); [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2009/022350s000\\_MedR\\_P3.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_MedR_P3.pdf) (accessed August 29, 2015)
- U.S. Food and Drug Administration. Tradjenta (Linagliptin) Tablets. Drug Approval Package. Medical Review. NDA 201280. [Internet]. 2011. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2011/201280Orig1s000MedR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000MedR.pdf) (accessed August 29, 2015)
- U.S. Food and Drug Administration. Januvia (Sitagliptin) Tablets. Drug Approval Package. Medical Review. NDA 21995. [Internet]. 2006. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2006/021995s000\\_MedR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_MedR.pdf) (accessed August 29, 2015)
- U.S. Food and Drug Administration. Nesina (Alogliptin) Tablets. Drug Approval Package. NDA 201280. [Internet]. 2013. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2013/022271Orig1s000MedRedt2.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000MedRedt2.pdf) (accessed August 29, 2015)
- U.S. Food and Drug Administration. Invokana (Canagliflozin) Tablets. Drug Approval Package. Medical Review. NDA 204042. [Internet]. 2013. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2013/204042Orig1s000MedR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000MedR.pdf) (accessed August 29, 2015)
- U.S. Food and Drug Administration. Farxiga (Dapagliflozin) Tablets. Drug Approval Package. Medical Review. NDA 202293. [Internet]. 2014. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2014/202293Orig1s000MedR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000MedR.pdf) (accessed August 29, 2015)
- U.S. Food and Drug Administration. Jardiance (Empagliflozin) Tablets. Drug Approval Package. Medical Review. NDA 204629. [Internet]. 2014. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2014/204629Orig1s000TOC.cfm](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204629Orig1s000TOC.cfm) (accessed September 15, 2015)
- U.S. Food and Drug Administration. Victoza (Liraglutide) rDNA Injection. Drug Approval Package. Medical Review. NDA 22341. [Internet]. 2010. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2010/022341s000medr\\_P1.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000medr_P1.pdf); [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2010/022341s000medr\\_P2.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000medr_P2.pdf) (accessed August 29, 2015)
- U.S. Food and Drug Administration. Byetta (Exenatide) Injection. Drug Approval Package. NDA 21773. [Internet]. 2005. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2005/021773\\_Byetta\\_medr.PDF](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_medr.PDF) (accessed August 29, 2015)
- Hirst JA, Farmer AJ, Ali R, et al. Quantifying the effect of metformin treatment and dose on glycemic control. *Diabetes Care* 2012;35:446-454
- U.S. Food and Drug Administration. Glucovance (Glyburide and Metformin Hydrochloride) Tablets. Drug Approval Package. Medical Review. NDA 21178. [Internet]. 2000. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2000/21-178\\_Glucovance\\_Medr\\_P1.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-178_Glucovance_Medr_P1.pdf); [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2000/21-178\\_Glucovance\\_Medr\\_P2.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-178_Glucovance_Medr_P2.pdf) (accessed August 29, 2015)
- Hirst JA, Farmer AJ, Dyar A, et al. Estimating the effect of sulfonyleurea on HbA1c in diabetes: a systematic review and meta-analysis. *Diabetologia* 2013;56:973-984
- Van de Laar FA, Lucassen PLBJ, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2005, Issue 2. Art. No.:CD003639

## Page 5: Risk of Hypoglycemia with Glucose Lowering Medications; Effect of Glucose Lowering Medications on Body Weight

1. Canadian Agency for Drugs and Technologies in Health. Second-line pharmacotherapy for type 2 diabetes-Update. Ottawa: The Agency; 2013 (CADTH optimal use report; vol.3, no.1a). [Internet]. [https://www.cadth.ca/sites/default/files/pdf/OP0512\\_DiabetesUpdate\\_Second-line\\_e.pdf](https://www.cadth.ca/sites/default/files/pdf/OP0512_DiabetesUpdate_Second-line_e.pdf). (accessed August 29, 2015)
2. Canadian Agency for Drugs and Technologies in Health. Third-line pharmacotherapy for type 2 diabetes-Update. Ottawa: The Agency; 2013 (CADTH optimal use report; vol.3, no.1b). [Internet]. [https://www.cadth.ca/sites/default/files/pdf/OP0512\\_Diabetes%20Update\\_Third-line\\_e.pdf](https://www.cadth.ca/sites/default/files/pdf/OP0512_Diabetes%20Update_Third-line_e.pdf) (accessed August 29, 2015)
3. Canadian Agency for Drugs and Technologies in Health. Second-line therapy for patients with diabetes inadequately controlled on metformin: a systematic review and cost-effectiveness analysis. Ottawa: The Agency;2010 (CADTH optimal therapy report; vol.4, issue 2). [Internet]. [https://www.cadth.ca/sites/default/files/pdf/C1110\\_SR\\_Report\\_final\\_e.pdf](https://www.cadth.ca/sites/default/files/pdf/C1110_SR_Report_final_e.pdf) (accessed August 29, 2015)
4. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes. A systematic review and meta-analysis. *Ann Intern Med* 2013;159:262-274
5. Bennett W, Maruthur N, Singh Sonal, et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. *Ann Intern Med* 2011;154:602-613
6. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. *Ann Intern Med* 2007;147:386-99
7. Schopman JE, Simon ACR, Hoefnagel SJM, et al. The incidence of mild and severe hypoglycemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. *Diabetes Metab Res Rev* 2014;30:11-20
8. Landman GWD, de Bock GH, van Hateren JJ, et al. Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. *PLoS ONE* 2014;9(2):e82880
9. Hemmingsen B, Schroll JB, Wetterslev J, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trials sequential analysis. *CMAJ Open* 2014;2(3):E162-E175
10. Hemmingsen B, Schroll JB, Lund SS, et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2013, Issue 4. Art. No.:CD009008. WITHDRAWN: *Cochrane Database Syst Rev* 2015 Jul 29;7:CD009008

## Pages 6 to 7: Specific Considerations: Place in Therapy, Contraindications, Precautions, Adverse Events

1. Bennett W, Maruthur N, Singh Sonal, et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. *Ann Intern Med* 2011;154:602-613
2. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. *Ann Intern Med* 2007;147:386-99
3. Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2005, Issue 3. Art. No.:CD002966
4. Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. *PLoS Med* 2014;9(4):e10001204
5. Hemmingsen B, Schroll JB, Wetterslev J, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trials sequential analysis. *CMAJ Open* 2014;2(3):E162-E175
6. Selvin E, Bolen S, Hsin-Chieh Y, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. *Arch Intern Med* 2008;168(19):2070-2080
7. Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. *Diabetologia* 2012;55:2593-2603
8. Product Monograph. Glucophage (metformin hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
9. U.S. Food and Drug Administration. Glumetza Metformin Hydrochloride Extended-Release Tablets. Drug Approval Package. Medical Review. NDA 21748. [Internet]. 2005. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2005/021748s000\\_Glumetza\\_MedR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021748s000_Glumetza_MedR.pdf) (accessed August 29, 2015)
10. De Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. *BMJ* 2010;340:c2181
11. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2010, Issue 4. Art.No.:CD002967
12. Hemmingsen B, Schroll JB, Lund SS, et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2013, Issue 4. Art. No.:CD009008. WITHDRAWN: *Cochrane Database Syst Rev* 2015 Jul 29;7:CD009008
13. Canadian Agency for Drugs and Technologies in Health. Health Technology Inquiry Service. Gliclazide MR versus glyburide for management of type 2 diabetes: A review of the clinical effectiveness and safety. 03 March 2009. [https://www.cadth.ca/media/pdf/DM/HTA\\_Gliclazide\\_vs\\_Glyburide.pdf](https://www.cadth.ca/media/pdf/DM/HTA_Gliclazide_vs_Glyburide.pdf) (accessed August 29, 2015)
14. Canadian Agency for Drugs and Technologies in Health. Rapid Response Report: Summary With Critical Appraisal. Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of clinical effectiveness and safety. 15 June 2011. <https://www.cadth.ca/glyburide-gliclazide-or-glimepiride-elderly-type-2-diabetes-review-clinical-effectiveness-and-safety> (accessed August 29, 2015)



15. Canadian Agency for Drugs and Technologies in Health. Rapid Response Report: Summary With Critical Appraisal. Glyburide, gliclazide or glimepiride in the elderly patients with type 2 diabetes: an updated review of clinical effectiveness and safety. 20 Aug 2015. <https://www.cadth.ca/glyburide-gliclazide-glimepiride-elderly-type2-diabetes> (accessed August 29, 2015)
16. Landman GWD, de Bock GH, van Hateren JJ, et al. Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. *PLoS ONE* 2014;9(2):e82880
17. Simpson SH, Lee J, Choi S, Vandermeer B, et al. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. *Lancet Diabetes Endocrinol* 2015;3(1):43-51
18. Product Monograph. Diabeta (glyburide). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
19. Product Monograph. Diamicon (gliclazide). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
20. Product Monograph. Amaryl (glimepiride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
21. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. *Ann Allergy Asthma Immunol* 2010;105(4):259-273
22. Product Monograph. GlucoNorm (repaglinide). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
23. U.S. Department of Veterans Affairs. VA/DoD Clinical Practice Guidelines. Management of Diabetes Mellitus in Primary Care (2010). [Internet]. <http://www.healthquality.va.gov/guidelines/cd/diabetes/> (accessed August 29, 2015)
24. Product Monograph. Glucobay (acarbose). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
25. Van de Laar FA, Lucassen PLBJ, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2005, Issue 2. Art. No.:CD003639
26. Product Monograph. Actos (pioglitazone hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
27. Product Monograph. Avandia (rosiglitazone maleate). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
28. Health Canada. Dear Healthcare Professional Letter. Avandia, Avandamet and Avandaryl – Important new restrictions on the use of rosiglitazone products due to information on cardiovascular related events – for health professionals. November 9, 2010. <http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2010/14591a-eng.php> (accessed August 29, 2015)
29. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. *CMAJ* 2009;180(1):32-39
30. Turner R, Kwok C, Chen-Turner C, et al. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. *Br J Clin Pharmacol* 2013;78:258-73.
31. Product Monograph. Forxiga (dapagliflozin propanediol monohydrate). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
32. Singh S, Loke YK, Furberg CD. Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis. *Thorax* 2011;66:383-388
33. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs – FDA and EMA assessment. *N Engl J Med* 2014;370(9):794-797
34. Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. *BMJ* 2014;348:g2366
35. U.S. Food and Drug Administration. Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. [Internet]. <http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf> (accessed August 28, 2015)
36. Product Monograph. Onglyza (saxagliptin hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
37. Product Monograph. Trajenta (linagliptin). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
38. Product Monograph. Januvia (sitagliptin phosphate monohydrate). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
39. Product Monograph. Nesina (alogliptin benzoate). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
40. Product Monograph. Invokana (anhydrous canagliflozin). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
41. Product Monograph. Jardiance (empagliflozin). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed September 15, 2015)
42. Health Canada. Information Update. Forxiga, Invokana: Health Canada begins safety review of diabetes drugs known as SGLT2 inhibitors and risk of ketoacidosis. [Internet]. <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/53892a-eng.php> June 22, 2015. (accessed June 22, 2015)
43. U.S. Food and Drug Administration. Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. [Internet]. <http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm>. May 15, 2015. (accessed May 15, 2015)
44. European Medicines Agency. Review of diabetes medicines called SGLT2 inhibitors started. Risk of diabetic ketoacidosis to be examined. [Internet]. [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2\\_inhibitors/human\\_referral\\_prac\\_000052.jsp&mid=WC0b01ac05805c516f](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2_inhibitors/human_referral_prac_000052.jsp&mid=WC0b01ac05805c516f). June 12, 2015. (accessed June 12, 2015)
45. U.S. Food and Drug Administration. Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fractures risk and new information on decreased bone mineral density. [Internet]. <http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm>. Sept 10, 2015. (accessed Sept 10, 2015)
46. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes. A systematic review and meta-analysis. *Ann Intern Med* 2013;159:262-274

47. Product Monograph. Victoza (liraglutide). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
48. Product Monograph. Byetta (exenatide injection). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)

**Pages 8 to 11: Glucose Lowering Medications, Dosage Forms, Dosing, Renal Considerations, Drug Interactions, Cost**

1. Lexicomp Online. [Internet]. <https://online.lexi.com/> (accessed August 29, 2015)
2. Product Monograph. Glucophage (metformin hydrochloride). [Internet] <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
3. Product Monograph. Glumetza (metformin hydrochloride extended release tablets). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
4. Product Monograph. Glucophage (metformin hydrochloride). Canadian Pharmacists Association, 2015. CPS [Internet]. <https://www.e-therapeutics.ca> (accessed August 29, 2015)
5. National Institute for Health and Care Excellence. Type 2 diabetes. NICE clinical guideline 87. <http://www.nice.org.uk/guidance/cg87> (accessed August 29, 2015)
6. U.S. Food and Drug Administration. Glumetza Metformin Hydrochloride Extended-Release Tablets. Drug Approval Package. Medical Review. NDA 21748. [Internet]. 2005. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2005/021748s000\\_Glumetza\\_MedR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021748s000_Glumetza_MedR.pdf) (accessed August 29, 2015)
7. Product Monograph. Diabeta (glyburide). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
8. Product Monograph. Diamicon (gliclazide). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
9. Product Monograph. Diamicon MR (gliclazide modified release). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
10. Product Monograph. Amaryl (glimepiride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
11. Product Monograph. GlucoNorm (repaglinide). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
12. Health Canada. Recalls & alerts. Gluconorm (repaglinide) – New Contraindication for Concomitant Use with Clopidogrel. July 31, 2015. <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/54454a-eng.php>. (accessed July 31, 2015)
13. Product Monograph. Glucobay (acarbose). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
14. Product Monograph. Avandia (rosiglitazone maleate). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
15. Product Monograph. Avandamet (rosiglitazone maleate/metformin hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
16. Product Monograph. Actos (pioglitazone hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
17. Product Monograph. Onglyza (saxagliptin hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
18. Product Monograph. Komboglyze (saxagliptin hydrochloride and metformin hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
19. Product Monograph. Trajenta (linagliptin). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
20. Product Monograph. Jentadueto (linagliptin and metformin hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
21. Product Monograph. Januvia (sitagliptin phosphate monohydrate). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
22. Product Monograph. Janumet (sitagliptin phosphate monohydrate and metformin hydrochloride), Janumet XR (sitagliptin phosphate monohydrate and metformin hydrochloride modified-release tablets). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
23. Product Monograph. Nesina (alogliptin benzoate). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
24. Product Monograph. Kazano (alogliptin benzoate and metformin hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
25. Product Monograph. Invokana (anhydrous canagliflozin). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
26. Product Monograph. Forxiga (dapagliflozin propanediol monohydrate). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
27. Product Monograph. Jardiance (empagliflozin). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed September 15, 2015)
28. Product Monograph. Victoza (liraglutide). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
29. Product Monograph. Byetta (exenatide injection). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)

**Page 8: Potential Risk Factors for Hypoglycemia**

1. Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycemic control versus targeting conventional glycemic control for type 2 diabetes mellitus (Review). Cochrane Database Syst Rev 2013, Issue 11. Art. No.:CD008143. WITHDRAWN: Cochrane Database Syst Rev 2015 Jul 29;7:CD008143
2. Product Monograph. Glucophage (metformin hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
3. Product Monograph. Diabeta (glyburide). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015) (accessed August 29, 2015)

4. Product Monograph. Diamicon (gliclazide). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
5. Product Monograph. Amaryl (glimepiride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
6. Product Monograph. GlucoNorm (repaglinide). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
7. Product Monograph. Glucobay (acarbose). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
8. Product Monograph. Avandia (rosiglitazone maleate). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
9. Product Monograph. Actos (pioglitazone hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
10. Product Monograph. Januvia (sitagliptin phosphate monohydrate). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
11. Product Monograph. Onglyza (saxagliptin hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
12. Product Monograph. Trajenta (linagliptin). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
13. Product Monograph. Nesina (alogliptin benzoate). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
14. Product Monograph. Invokana (anhydrous canagliflozin). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
15. Product Monograph. Forxiga (dapagliflozin propanediol monohydrate). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
16. Product Monograph. Jardiance (empagliflozin). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed September 15, 2015)
17. Product Monograph. Victoza (liraglutide). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
18. Product Monograph. Byetta (exenatide injection). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)

#### Appendix: Glucose Lowering Medications and Diabetes Related Outcomes

1. Bennett W, Maruthur N, Singh Sonal, et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. *Ann Intern Med* 2011;154:602-613
2. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. *Ann Intern Med* 2007;147:386-99
3. Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus (Review). *Cochrane Database of Systematic Reviews* 2005, Issue 3. Art. No.:CD002966
4. Hemmingsen B, Schroll JB, Wetterslev J, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trials sequential analysis. *CMAJ Open* 2014;2(3):E162-E175
5. Selvin E, Bolen S, Hsin-Chieh Y, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. *Arch Intern Med* 2008;168(19):2070-2080
6. Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. *PLoS Med* 2014;9(4):e10001204
7. Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. *Diabetologia* 2012;55:2593-2603
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998;352:854-865
9. Ewart RM. The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study. *BMJ* 2001;323:854-858
10. Nathan DM. Some answers, more controversy, from UKPDS. *Lancet* 1998;352:832-833
11. Hemmingsen B, Schroll JB, Lund SS, et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus (Review). *Cochrane Database of Systematic Reviews* 2013, Issue 4. Art. No.:CD009008; WITHDRAWN: *Cochrane Database Syst Rev* 2015 Jul 29;7:CD009008
12. Canadian Agency for Drugs and Technologies in Health. Second-line pharmacotherapy for type 2 diabetes-Update. Ottawa: The Agency; 2013 (CADTH optimal use report; vol.3, no.1a). [Internet]. [https://www.cadth.ca/sites/default/files/pdf/OP0512\\_DiabetesUpdate\\_Second-line\\_e.pdf](https://www.cadth.ca/sites/default/files/pdf/OP0512_DiabetesUpdate_Second-line_e.pdf). (accessed August 29, 2015)
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352:837-53
14. Product Monograph. Diabeta (glyburide). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
15. Product Monograph. Diamicon (gliclazide). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
16. Product Monograph. Amaryl (glimepiride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
17. Black C, Donnelly P, McIntyre L, et al. Meglitinide analogues for type 2 diabetes mellitus (Review). *Cochrane Database of Systematic Reviews* 2007, Issue 2. Art. No.:CD004654
18. Canadian Agency for Drugs and Technologies in Health. Third-line pharmacotherapy for type 2 diabetes-Update. Ottawa: The Agency; 2013 (CADTH optimal use report; vol.3, no.1b). [Internet]. [https://www.cadth.ca/sites/default/files/pdf/OP0512\\_Diabetes%20Update\\_Third-line\\_e.pdf](https://www.cadth.ca/sites/default/files/pdf/OP0512_Diabetes%20Update_Third-line_e.pdf) (accessed August 29, 2015)
19. Van de Laar FA, Lucassen PLBJ, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review). *Cochrane Database of Systematic Reviews* 2005, Issue 2. Art. No.:CD003639
20. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Pioglitazone for type 2 diabetes mellitus (Review). *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.:CD006060

21. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Rosiglitazone for type 2 diabetes mellitus (Review). *Cochrane Database of Systematic Reviews* 2007, Issue 3. Art. No.:CD006063
22. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet* 2005;366:1279-89
23. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicenter, randomised, open-label trial. *Lancet* 2009;373:2125-2135
24. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus. *Am J Cardiovasc Drugs* 2011;11(2):115-128
25. Product Monograph. Actos (pioglitazone hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
26. Product Monograph. Avandia (rosiglitazone maleate). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/> (accessed August 29, 2015)
27. European Medicines Agency. Press release. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. September 9, 2010. [http://www.ema.europa.eu/ema/index.jsp?curl=pages/news\\_and\\_events/news/2010/09/news\\_detail\\_001119.jsp&mid=WC0b01ac058004d5c1](http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&mid=WC0b01ac058004d5c1) (accessed August 29, 2015)
28. Health Canada. Dear Healthcare Professional Letter. Avandia, Avandamet and Avandaryl – Important new restrictions on the use of rosiglitazone products due to information on cardiovascular related events – for health professionals. November 9, 2010. <http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2010/14591a-eng.php> (accessed August 29, 2015)
29. U.S. Food and Drug Administration. FDA Drug Safety Communication. FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines. November 25, 2013. <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm376683.htm> (accessed August 29, 2015)
30. Nissen SE, Wolski K. Rosiglitazone revisited. An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. *Arch Intern Med* 2010;170(14):1191-1201
31. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. *BMJ* 2012;344:e1369
32. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus (Review). *Cochrane Database of Systematic Reviews* 2008, Issue 2. Art. No.:CD006739
33. U.S. Food and Drug Administration. Onglyza Saxagliptin Tablets. Drug Approval Package. Medical Review. NDA 22350. [Internet]. 2009. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2009/022350s000\\_MedR\\_P1.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_MedR_P1.pdf); [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2009/022350s000\\_MedR\\_P2.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_MedR_P2.pdf); [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2009/022350s000\\_MedR\\_P3.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022350s000_MedR_P3.pdf) (accessed August 29, 2015)
34. U.S. Food and Drug Administration. Tradjenta Linagliptin Tablets. Drug Approval Package. Medical Review. NDA 201280. [Internet]. 2011. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2011/201280Orig1s000MedR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000MedR.pdf) (accessed August 29, 2015)
35. U.S. Food and Drug Administration. Januvia Sitagliptin Tablets. Drug Approval Package. Medical Review. NDA 21995. [Internet]. 2006. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2006/021995s000\\_MedR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_MedR.pdf) (accessed August 29, 2015)
36. U.S. Food and Drug Administration. Nesina Alogliptin Tablets. Drug Approval Package. NDA 201280. [Internet]. 2013. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2013/022271Orig1s000MedRedt2.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000MedRedt2.pdf) (accessed August 29, 2015)
37. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with Type 2 Diabetes Mellitus. *N Engl J Med* 2013;369:1317-1326
38. U.S. Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee. Briefing Information for the April 14, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC). <http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm442059.htm> (accessed August 29, 2015)
39. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in Type 2 Diabetes. *N Engl J Med*; 2015;373:232-42
40. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with Type 2 Diabetes. *N Engl J Med* 2013;369:1327-1335
41. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes. A systematic review and meta-analysis. *Ann Intern Med* 2013;159:262-274
42. U.S. Food and Drug Administration. Invokana Canagliflozin Tablets. Drug Approval Package. Medical Review. NDA 204042. [Internet]. 2013. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2013/204042Orig1s000MedR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000MedR.pdf) (accessed August 29, 2015)
43. U.S. Food and Drug Administration. Farxiga Dapagliflozin Tablets. Drug Approval Package. Medical Review. NDA 202293. [Internet]. 2014. U.S. Food and Drug Administration. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2014/202293Orig1s000MedR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000MedR.pdf) (accessed August 29, 2015)
44. U.S. Food and Drug Administration. Jardiance Empagliflozin Tablets. Drug Approval Package. Medical Review. NDA 204629. [Internet]. 2014. U.S. Food and Drug Administration. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2014/204629Orig1s000TOC.cfm](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204629Orig1s000TOC.cfm) (accessed September 16, 2015)
45. Zinman B, Wanner C, Lachin J, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. *N Engl J Med* 2015; epub September 17, 2015
46. Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus (Review). *Cochrane Database of Systematic Reviews* 2011, Issue 10. Art. No.:CD006423



47. Wu S, Sun F, Zhang Y, et al. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials. *J Clin Pharm Therap* 2014;39:7-13
48. U.S. Food and Drug Administration. Victoza Liraglutide rDNA Injection. Drug Approval Package. Medical Review. NDA 22341. [Internet]. 2010. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2010/022341s000medr\\_P1.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000medr_P1.pdf); [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2010/022341s000medr\\_P2.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000medr_P2.pdf) (accessed August 29, 2015)
49. U.S. Food and Drug Administration. Byetta Exenatide Injection. Drug Approval Package. NDA 21773. [Internet]. 2005. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2005/021773\\_Byetta\\_medr.PDF](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_Byetta_medr.PDF) (accessed August 29, 2015)
50. ClinicalTrials.gov. Thiazolidinediones or sulphonylureas and cardiovascular accidents. Intervention trial (TOSCA IT). ClinicalTrials.gov Identifier: NCT00700856. <https://clinicaltrials.gov/> (accessed August 29, 2015)
51. ClinicalTrials.gov. Cardiovascular and renal microvascular outcome study with linagliptin in patients with type 2 diabetes mellitus (CARMELINA). ClinicalTrials.gov Identifier: NCT01897532. <https://clinicaltrials.gov/> (accessed August 29, 2015)
52. ClinicalTrials.gov. CAROLINA: cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes. ClinicalTrials.gov Identifier: NCT01343424. <https://clinicaltrials.gov/> (accessed August 29, 2015)
53. ClinicalTrials.gov. CANVAS-CANagliflozin cardiovascular Assessment Study. ClinicalTrials.gov Identifier: NCT01032629. <https://clinicaltrials.gov/> (accessed August 29, 2015)
54. ClinicalTrials.gov. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). ClinicalTrials.gov Identifier: NCT01730534. <https://clinicaltrials.gov/> (accessed August 29, 2015)
55. ClinicalTrials.gov. Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER). ClinicalTrials.gov Identifier: NCT01179048. <https://clinicaltrials.gov/> (accessed August 29, 2015)
56. ClinicalTrials.gov. Exenatide study of cardiovascular event lowering trial (EXSCCEL). ClinicalTrials.gov Identifier: NCT01144338. <https://clinicaltrials.gov/> (accessed August 29, 2015)